The Dutch National ADS centre includes the NMOSD centre, Paediatric MS centre (Rotterdam) and Sanquin diagnostic services (Amsterdam). 9 We here aim to provide an incidence estimate of MOG-IgG seropositivity in a typical western European country and to describe the clinical and serological characteristics of patients within the MOG-IgG spectrum. In addition, a recent study showed that the distribution of clinical phenotypes differs between MOG-IgG-seropositive children and adults. 6 This provides an unique opportunity to gain insight into the nationwide incidence of MOG-IgG seropositivity in both children and adults presenting with CNS demyelinating diseases. In the Netherlands, one single centralised laboratory performs the diagnostic testing of MOG-IgG. 8 Although research on the clinical aspect of MOG-IgG-associated demyelinating syndromes has taken a great leap in the recent years, the incidence figures of MOG-IgG seropositivity in the general population have not yet been investigated. 6, 7 Since the optimisation of the MOG-IgG cell-based assay (CBA), this CBA has become available for routine clinical practice. 3, 4 MOG-IgG are found in subtypes of central nervous system (CNS) acquired demyelinating syndromes (ADS) in both adult and paediatric patients, for example, in neuromyelitis optica spectrum disorders (NMOSD), 5 acute disseminated encephalomyelitis (ADEM) and in a small subgroup of adult multiple sclerosis (MS) patients. 1, 2 Anti-MOG antibodies (MOG-IgG) can cause demyelination in vitro and induce experimental autoimmune encephalomyelitis. Myelin oligodendrocyte glycoprotein (MOG) is a protein expressed on the surface of myelin sheaths and oligodendrocytes.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |